These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19439722)

  • 1. Seeing injectable MS therapies differently: they are more similar than different.
    Fox RJ; Arnold DL
    Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 4. Seeing injectable ms therapies differently: they are more similar than different.
    Johnson KP; Fox RJ; Arnold DL
    Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.
    Toprak MK; Cakir B; Ulu EM; Arat Z; Benli US; Can U; Ağildere M
    Int J Neurosci; 2008 Dec; 118(12):1645-58. PubMed ID: 18937112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High sensitivity measurement of CRP and disease progression in multiple sclerosis.
    Soilu-Hänninen M; Koskinen JO; Laaksonen M; Hänninen A; Lilius EM; Waris M
    Neurology; 2005 Jul; 65(1):153-5. PubMed ID: 16009907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of MRI as an outcome measure in clinical trials.
    Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
    Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B; Tremlett H
    Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
    [No Abstract]   [Full Text] [Related]  

  • 9. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK
    Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
    Cristiano E
    Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
    Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
    Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of interferon-beta in the treatment of multiple sclerosis.
    Derwenskus J; Lublin FD
    Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
    [No Abstract]   [Full Text] [Related]  

  • 15. CSF analysis in suspected MS: do bands aid?
    Hintzen RQ; Giovannoni G
    Neurology; 2008 Mar; 70(13 Pt 2):1059-60. PubMed ID: 18362264
    [No Abstract]   [Full Text] [Related]  

  • 16. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images.
    Barkhof F; van Waesberghe JH; Uitdehaag BM; Polman CH
    Ann Neurol; 1997 Dec; 42(6):982. PubMed ID: 9403493
    [No Abstract]   [Full Text] [Related]  

  • 20. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.
    Freedman MS; Forrestal FG
    Mult Scler; 2008 Nov; 14(9):1234-41. PubMed ID: 18632774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.